Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose.
Researchers have identified distinct differences among the cells comprising a tissue in the retina that is vital to human visual perception. The scientists from the National Eye Institute (NEI) discovered five subpopulations of retinal pigment epithelium.
Molecular and cellular changes in rod photoreceptors are detectable in a mouse model of retinal degeneration several days prior to observable morphological changes, according to researchers at the National Eye Institute.
The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program called Blueprint Neurotherapeutics Network helps basic researchers prep for clinical trials and regulatory approval.
New research by National Eye Institute (NEI) investigators shows that while microsaccades seem to boost or diminish the strength of the brain signals underlying attention, eye movements are not drivers of those brain signals.
Researchers at the National Eye Institute (NEI) have discovered that power-producing organelles in the eye’s photoreceptor cells, called mitochondria, function as microlenses that help channel light to these cells’ outer segments.